Position: Professor
School/Academic Group: School of Pharmaceutical Sciences
Email: baishan_jiang@whu.edu.cn
Education：
2001–2005 Xiangtan University, Bachelor
2005–2011 Chinese Academy of Sciences of Biomedicine and Health, Ph.D.
Working Experience：
2011.7–2015.8 Chinese Academy of Sciences of Biomedicine and Health, Assistant Researcher
2015.9–2019.3 Harvard Medical School, Postdoc
2019.4–2022.1 Harvard Medical School, Research Scientist,
2022.2–Present Wuhan University, Professor
Research Interests:
Small Molecule Inhibitors and Protein Degraders
Publications：
1. Li, Q. +; Jiang, B. +; Guo, J. +; Shao, H.; Del Priore, I. S.; Chang, Q.; Kudo, R.; Li, Z.; Razavi, P.; Liu, B.; Boghossian, A. S.; Rees, M. G.; Ronan, M. M.; Roth, J. A.; Donovan, K. A.; Palafox, M.; Reis-Filho, J. S.; de Stanchina, E.; Fischer, E. S.; Rosen, N.; Serra, V.; Koff, A.; Chodera, J. D.; Gray, N. S.; Chandarlapaty, S., INK4 tumor suppressor proteins mediate resistance to CDK4/6 kinase inhibitors. Cancer Discovery 2021, doi: 10.1158/2159-8290.CD-20-1726 (+equal contribution).
2. Jiang, B. +; Jiang, J. +; Kaltheuner, I. H. +; Iniguez, A. B.; Anand, K.; Ferguson, F. M.; Ficarro, S. B.; Alex Seong, B. K.; Greifenberg, A. K.; Dust, S.; Kwiatkowski, N. P.; Marto, J. A.; Stegmaier, K.; Zhang, T.; Geyer, M.; Gray, N. S., Structure-Activity Relationship Study of THZ531 Derivatives Enables the Discovery of BSJ-01-175 as a Dual CDK12/13 Covalent Inhibitor with Efficacy in Ewing Sarcoma. Eur. J. Med. Chem. 2021, 221, 113481-113497 (+equal contribution).
3. Jiang, B. +; Yang, G. +; Che, J. +; Lu, W.; Kaltheuner, I. H.; Dries, R.; Kalocsay, M.; Berberich, M. J.; Jiang, J.; You, I.; Kwiatkowski, N.; Riching, K. M.; Daniels, D. L.; Sorger, P. K.; Geyer, M.; Zhang, T.; Gray, N. S., Discovery and resistance mechanism of a selective CDK12 degrader. Nat Chem Biol 2021, 17, 675-683 (+equal contribution).
4. Jiang, J. +; Jiang, B+.; Jarrod, S.; Zhang, T.H.; Gray, N.S., Characterization of a dual covalent inhibitor targeting MKK4 and MKK7. Cell Chem. Biol. 2020, 27, 1553-1560 (+equal contribution).
5. Jiang, B. +; Wang, E. S. +; Donovan, K. A.; Liang, Y.; Fischer, E. S.; Zhang, T.; Gray, N. S., Development of dual and selective degraders of cyclin-dependent kinases 4 and 6. Angew. Chem. Int. Edit., 2019, 58, 6321-6326 (equal contribution).
6. Brand, M.+; Jiang, B. +; Bauer, S.; Donovan, K. A.; Wang, E. S.; Nowak, R. P.; Yuan, J. C.; Zhang, T.; Kwiatkowski, N.; Müller, A. C.; Fischer, E. S.; Gray, N. S.; Winter, G. E., Homolog-selective degradation as a strategy to probe the function of CDK6 in AML. Cell Chem. Biol., 2019, 26, 300-306 (equal contribution).
7. Browne, C. M.; Jiang, B.; Ficarro, S. B.; Doctor, Z. M.; Johnson, J. L.; Card, J. D.; Sivakumaren, S. C.; Alexander, W. M.; Yaron, T.; Murphy, C. J.; Kwiatkowski, N. P.; Zhang, T.; Cantley, L. C.; Gray, N. S.; Marto, J. A. A Chemoproteomic Strategy for Direct and Proteome-wide Covalent Inhibitor Target-site Identification. J. Am. Chem. Soc. 2019, 141, 191-203.
8. Olson, C. M.; Jiang, B.; Erb, M. A.; Liang, Y.; Doctor, Z. M.; Zhang, Z.; Zhang, T.; Kwiatkowski, N.; Boukhali, M.; Green, J. L.; Haas, W.; Fischer, E. S.; Young, R. A.; Bradner, J. E.; Winter, G. E.; Gray, N. S., Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. Nature Chem. Biol., 2018, 14, 163-170.
